Largecap News Today — November 10, 2026
SoftBank swings to $7 billion net loss in second quarter as tech selloff weighs on results and more — today's largecap signal.
Investors are navigating a complex landscape of market volatility and shifting economic trends. SoftBank's significant $7 billion net loss in the second quarter serves as a stark reminder of the tech sector's challenges, as the selloff in technology stocks continues to impact major players. This same volatility is reflected in the Dow, which has experienced its third 1,000-point swing in just four days, suggesting that market fluctuations are far from over.
Against this backdrop of market uncertainty, other significant developments are unfolding. In the pharmaceutical space, Eli Lilly's obesity pill has shown promising results in a late-stage trial for treating sleep apnea, potentially paving the way for approval. Meanwhile, concerns have emerged about the safety of certain popular GLP-1 drugs, such as Ozempic and Zepbound, which may carry a risk of vision loss. As the market continues to digest these developments, investors are also keeping an eye on the policy front, where proposals to ensure the long-term solvency of Social Security are being debated, and the AI sector, where Anthropic's release of new frontier models is fueling speculation about a potential IPO.
Today's signal:
• SoftBank swings to $7 billion net loss in second quarter as tech selloff weighs on results (cnbc.com)
• Here’s how Bernie Sanders wants to keep Social Security solvent ‘for generations’ (marketwatch.com)
• Dow sees its third 1,000-point swing in four days. Why the volatility isn’t over yet. (marketwatch.com)
• Anthropic releases first frontier models since Amodei's call for slowdown as IPO buzz builds (cnbc.com)
• Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss (marketwatch.com)
• Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval (cnbc.com)